Similar Posts
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab
ByInnokeys
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. The…
June 2017: Poster Presentation at ANZCHOG 2017
ByInnokeys
Adelaide, South Australia (June 20, 2017) – Innokeys Pte Ltd attended ANZCHOG 2017 – a conference which is organized annually by the…
ASCO 2013 : Nimotuzumab Abstracts
ByInnokeys
Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…
July 2015: Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
ByInnokeys
Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG • The acquisition enables Innokeys to fully lead clinical and commercial development…
Patent Pending for “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in numerous countries
ByInnokeys
Application for patents with the title of “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” are…
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
ByInnokeys
MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys…